T he decision to seek oncology care at research centers often mandates that patients leave their home communities, interact with unfamiliar physicians and care providers, and follow a course of care that has a substantial research component in which the outcomes are difficult to predict. An important element of cancer research is helping patients arrive at satisfactory decisions about their medical options, including participating in a clinical trial. The juxtaposition of research and cancer care requires that due diligence be given to ensure patients have a clear understanding of the decisions they face. Making decisions in these circumstances is rarely straightforward, and numerous complex factors influence clinical decision-making processes.
In clinical research, informed consent is the process for addressing issues of decision making. The premise underlying informed consent is that an individual, once given adequate information, can then make a voluntary decision about engaging in whatever option is deemed best for the specific situation. The overwhelming majority of articles on cancer and decision making focus on communication patterns between patient and provider, 1Y3 patient participation in decision-making processes, 4Y6 and the provision of information. 7, 8 Evidence about the role of information with respect to decision making and informed consent is mixed. Some researchers found that giving patients more information and more time to arrive at a decision was associated with increased patient anxiety and lower consent rates. 9Y11 Other researchers reported, however, that providing additional information did not affect anxiety levels in either control or intervention groups. 12 Yet, patients exercising autonomous decision making may take into account emotions, values, social norms, environmental barriers, and financial limitations, in addition to factual information. 13 Researchers have long questioned the assumption underlying informed consent regulations, that is, that patients take a rational and objective approach to medical decision making.
14 To understand the decision-making process of seeking care at a US cancer referral center and the association of that decision to informed consent, a qualitative study was conducted to obtain the perspectives of cancer patients and their caregivers.
n Participants and Methods
Setting and Sample
Data were collected from a convenience sample of patients seen at a cancer clinic, located in the northwest United States, where approximately 550 people are treated with hematopoietic cell transplant (HCT) each year. All participants had to speak English and be 18 years or older with a Karnofsky score of greater than 80%. Patients also had to have consented to enroll in a phase 2 HCT clinical trial. Each of the clinical trials involved early-stage clinical research (haploidentical transplants, cord blood transplants, and tandem transplants) and so represented high-risk clinical research evaluating the safety of the respective procedures. These phase 2 trials were examining outcomes related to engraftment, durability of engraftment, incidence and severity of graft versus host disease, and associated morbidity and mortality. Following study approval by the institutional review board, clinical staff assisted in identifying potential eligible candidates. An investigator explained the study to each candidate, and consent to participate was obtained. At the time of consent, study patient participants were asked to identify 1 primary caregiver. These caregivers were then contacted and asked if they were willing to participate in the study.
Study Procedures
The study period spanned approximately 1 year, starting with a semistructured interview before HCT (time 1), followed by 2 additional interviews, with one conducted at approximately 80 days after HCT (time 2) and the last 12 to 18 months after HCT (time 3). Initial interviews were conducted by the investigators in a private setting in the clinic. Follow-up interviews at 80 and 365 days after HCT were conducted either in the clinic or via the telephone (for those participants not returning to the clinic for follow-up appointments). At the initial interview, each patient and caregiver were asked, ''How did you (or the person you are caring for) end up at this clinic?'' Follow-up questions were asked to probe more deeply into the details of the decision-making process, including ''When did you make the decision to participate in the clinical trial?'' ''Who or what influenced your decision?'' And ''who do you see as the primary decision maker?'' Interviews conducted at times 2 and 3 asked additional questions about decisional regret and usefulness of the phase 2 study informed consent document. All interviews were tape recorded and lasted approximately 1 hour or until no new information was heard. Recordings were transcribed, and accuracy of the transcription was checked against the original recordings by one of the investigators (DJD).
Data Analysis
Qualitative content analysis was the guiding research approach because this form of analysis deeply examines language within large areas of text and then condenses the text into manageable categories. 15 Shared understandings and meanings are represented in the created categories. Conventional content analysis was the particular form of analysis used for this study. In this method, researchers immerse themselves in the data and allow categories, themes, and insights to emerge, rather than approaching the text with some set of prescribed categories in mind. 16 Interview transcriptions were entered in the qualitative analytic software program HyperResearch (ResearchWare, Inc, Randolph, MA). Words, phrases, and sentences determined to be germane to developing themes were identified in the transcribed interviews. These units of analysis were then organized into common patterns and groupings based on their similarities. These categories were arranged into themes that answered the study's aim of describing patients' and caregivers' perspectives on cancer clinical trial decision making.
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Participant Characteristics
Twenty-five patients treated with HCT and 20 primary caregivers participated. Their ages ranged from 22 to 69 years, with a mean age of 54 years; 24 were women and 21 were men (Table 1) . Lymphoma was the most frequent diagnosis (n = 8; 32%; Table 1 ). Two patients (8%) died before day 80 (time 2), whereas 2 others were too ill to be reinterviewed at day 80. At the time 3 follow-up interview, an additional 8 patients had died, 1 had withdrawn from the study, and 2 others could not be contacted. Thus, a total of 10 patients (40%) had died by day 365. At time 1 (before HCT), 5 caregivers declined study participation. At time 2 (day 80), 15 caregivers were interviewed, and at time 3, 6 caregivers were interviewed. A caregiver was not reinterviewed if his/her patient had died.
Major Themes
Data about decision making were categorized into 3 principal themes: ''steps in decision making,'' ''reasons for deciding,'' and ''elements of informed consent.''
STEPS IN DECISION MAKING
Patients and caregivers described by whom, when, and where decisions were made regarding research participation. The timing and location of the decision occurred in 1 of 2 ways. For some (n = 18 patients, 72%; n = 12 caregivers, 60%), the decision rested on the recommendations of their referring oncologists, and the decision happened long before they had consulted with oncologists at the research center. These decisions often were made in locations geographically distant from the center, such that the patients and their caregivers arrived at the center fully intending to participate in any options that were offered (Table 2) .
Other patients traveled to the research center to consult with an oncologist and made the decision to stay for care by the conclusion of the consultation or very shortly thereafter. Most patients (n = 23, 92%) and caregivers (n = 15, 75%) agreed that the decision to pursue any offered option was made before receiving any information provided in the informed consent conference ( Table 2) .
REASONS FOR DECIDING
When asked to articulate the reasons for deciding to seek care at a cancer referral center, the most frequent reason was that patients (n = 15; 60%) and caregivers (n = 5; 25%) felt that they had ''no options'' or ''no choice'' if they wanted to extend life. Thus, with a disease that could not be cured by standard therapy and with the view that death in the future was not acceptable, the only ''choice'' was the one that offered the possibility of cure. Even though the ''choice'' entailed a clinical trial, these participants felt that the decision was an easy one to make.
For others, particularly for those who spent at least a year dealing with their disease, the decision was more difficult. Many patients with long-term diagnoses had been given conventional therapy, but they came to the center because the disease became resistant to conventional treatment. As one man explained: ''we weren't looking for a study, because we had talked to NIH [National Institutes of Health] back in '96 or so, when I was first diagnosed, and they had all kinds of studies going, but I just didn'tVat that point, their results weren't good, and I didn't need it. So, I've been kind of dragging my feet all along waiting for technology to catch up with my disease.''
The disease process itself influenced the alacrity and apparent ease or lack of ease with which decisions were reached. Repeatedly, participants talked about chemotherapy as being a temporary solution and indicated that transplant offered the only hope for a cure. A young woman diagnosed with nonHodgkin lymphoma explained, ''I want a cure. I don't want to go home to die.'' Cure was the single reason most frequently cited by patients (n = 19, 76%) for deciding to participate in an HCT research study; 8 caregivers (40%) also identified cure as the primary motivation (Table 2) .
Four patients also identified altruism as another reason to participate in research. Even if the transplant did not provide a cure or extend life, science would gain important knowledge from their participation, thereby benefiting future patients. Abbreviation: AML, acute myelogenous leukemia.
As one woman noted when asked about providing consent for various clinical trials, ''I said, ''Sure.'' That's partly why I'm here too, you know. I've got good treatment and I wanna give back too.'' Thus, for some, the desire to ensure cure of his/her own disease was accompanied by the altruistic motive of helping future patients.
ELEMENTS OF INFORMED CONSENT
Respect for autonomy is an essential element of the informed consent process and entails 3 elements in decision making. To be autonomous, a decision must be intentional, made with understanding, and free from the undue influence of medical staff. 17 With respect to the first and third elements of autonomous decision making, all patients in this study reported that their decisions were intentional, with 24 (96%) identifying themselves as the primary decision maker. The one patient who did not see himself as the primary caregiver was airlifted to the cancer clinic within a few days after the initial diagnosis of acute myelogenous leukemia and believed any decisions were solely that of the attending oncologist. None of the patients or family members identified any outside controlling influences governing their decision making. In keeping with the second element of autonomy, patients gained understanding through many avenues, including referring physicians, family, and friends. Even when patients discussed how there was no decision to make, they did consult with family members and their physicians. One patient stated, ''You know, the family really wanted me to do it. The kids and my wifeVand they wanted me to do it.'' Similarly, another patient, a woman who had teenage children commented, ''I feel like that I would be quitting [ like I was just quitting.'' In each case, the decision to participate in a clinical research study gave patients a course of action that allowed them to potentially attain the desired goals of maintaining family relationships, of being present in the lives of loved ones, and of finding a cure for the hematologic malignancy that currently threatened their lives. Consent forms can be an important dimension for offering understanding to people making complex decisions. When asked if they ever went back to reread the consents they had signed upon arrival to the cancer referral center, 18 (72%) of the 21 participants interviewed at time 2 stated they did not reread the consents. One did not comment on whether she did or not, but noted that the consent forms were ''overwhelming.'' Five individuals (24%) stated that they did reread their consents, with one noting, ''I was curious about what I had agreed to.'' One patient remarked that he ''skimmed'' the consent forms at the initial consenting conference, whereas 2 other patients admitted that they signed the consents without reading them ( Table 2 ).
In addition, several patients commented that they deliberately chose to ignore some of the information provided to them. One woman explained the information given to her before her consent conference included ''every medicine, and every side effect, and every consequence and every possible this, that, and the other. And it was just exhausting, and it was just scary.'' She decided she was not going to pay attention to ''all that nonsense,'' and she would ''deal with it'' if any of the risks became a reality. These findings underscore the complexity of the decision-making process participants experienced.
n Discussion
The 3 themes presented highlight the complexity of a decision to participate in a potentially lifesaving research study. Accepted criteria for evaluating informed consent include having the capacity to decide, disclosing relevant information, understanding the disclosure, acting voluntarily, and granting permission. 18 These elements are seen as encompassing the concept of autonomy and are essential components for the ethical conduct of research.
Findings from this study diverge from present-day decisionmaking models that depict research/clinical trial participation decisions as single events (usually at the time when the consent is signed) based on providing adequate cognitive information. The rational/informational domain encompasses provision of information and understanding, whereas the contractual/signatory domain encompasses clinical decision making and formal documentation of informed consent. Both of these domains rely on the cognitive processes of the person deciding to enroll in research clinical trials.
The rational/informational model has the appeal of providing information that promotes respect for autonomy as opposed to paternalism, because the patient makes the decision whether to participate supposedly based on ''information.'' Participation in clinical trials, however, often entails multiple decisions regarding possible courses of action and rarely is all the necessary information available at the initial encounter. In addition, individual and contextual factors can be ignored, including affective responses that play an important role in determining clinical trial participation. 19 Focusing on improving the communication of information in the consenting process may be misguided. For example, a short training program geared to improve the communication skills of oncologists in obtaining informed consent yielded little success. 20 The majority of patients (92%) made their decision to participate in transplant research before they arrived at the center without the information about the specific study and before they actually had the consent conference and consent documents for the specific study in which they ultimately enrolled. That many participants (72%) never referred back to the informed consent documentVwith some admitting to never reading the document to begin withVpoints to the notion that information perhaps is in fact not the most important consideration for some individuals. Continued efforts to increase patients' knowledge might serve little purpose for individuals who prefer to remain ''ignorant'' of particular information 21 and raise important questions about the documents themselves, as well as the timing of when these documents are provided to patients.
From participants' perspectives, decision making was a multidimensional process including, but not limited to the mandated informed consent event and documents. As Little and colleagues 22 observed in their study of 10 bone marrow transplant patients and their caregivers, the informed consent document can never provide enough information that will effectively convey the experience of going through such intense and risky therapy. Dresser 23 agreed, noting that clinical trial documents and consultation meetings are inadequate in providing patients a realistic understanding of the consequences of decisions made. Thus, the present-day practice of focusing on information is inherently inadequate.
Study Limitations and Strengths
Study limitations include utilization of a convenience sample; interviews were not conducted with patients who decided to pursue other options, including those who decided to let the disease run its course without further medical intervention. Also, the sample lacks diversity in terms of participants' race/ ethnicity and so limits its representation of the general US population. The major strength of this study is that it followed participants over an extended period after HCT. 
Conclusion
These findings add to the body of literature challenging the notion of using the rational/informational model of decision making as the sole vehicle through which informed consent is addressed. As McCaul and his associates 24 pointed out, the informed decision-making approach appeals because it appears to satisfy consenting requirements of patient autonomy, yet this approach may not culminate in the best decisions. Because 92% of all patients in this study reported making the research participation decision prior to informed consent conferences, perhaps the opportunity for dialogue about high-risk clinical trials consent conferences ought to occur before people travel to cancer referral centers.
The seriousness of the hematologic diagnosis and the high risk of death from the disease and/or the HCT itself create an ethical imperative beyond the provision of information. The discussion among cancer providers, researchers, and patients not only must be driven by regulatory mandates of providing cognitive ''information,'' but also must reflect the intense emotional component active in the decision-making process. The relegating of informed consent to a linear cognitive process denies the reality of decision making. The increased risk posed by disease diagnosis and the high morbidity and mortality of the research HCT can be discussed with patients. In consent discussions, providers and researchers must recognize that patients' sense of ''no option'' is directly linked to the risk of dying. Death is not only a statistical component for patients' decision making, it is also the backdrop against which research protocol participation is considered. We need not change the offering of information and the explanation of scientific reasoning in consent conferences. We must, however, allow for the expression of the depth of the emotion and the perception of risk that influences people, ''who have already decided what they intend to do.''
